Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
IN-UTERO HEMATOPOIETIC STEM-CELL TRANSPLANTATION - A STATUS-REPORT
Autore:
FLAKE AW; ZANJANI ED;
Indirizzi:
UNIV PENN,CHILDRENS HOSP,DEPT SURG,ABRAMSON PEDIAT RES CTR,ROOM 1102 D,34TH ST & CIV CTR BLVD PHILADELPHIA PA 19104 UNIV PENN,CHILDRENS HOSP,CTR FETAL DIAG & THERAPY PHILADELPHIA PA 19104 UNIV NEVADA,VET AFFAIRS MED CTR,DEPT MED RENO NV 89557
Titolo Testata:
JAMA, the journal of the American Medical Association
fascicolo: 11, volume: 278, anno: 1997,
pagine: 932 - 937
SICI:
0098-7484(1997)278:11<932:IHST-A>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
SEVERE COMBINED IMMUNODEFICIENCY; BONE-MARROW TRANSPLANTATION; INUTERO TRANSPLANTATION; SHEEP; ENGRAFTMENT; THERAPY; PERSISTENCE; EXPRESSION; CHIMERISM; GESTATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
49
Recensione:
Indirizzi per estratti:
Citazione:
A.W. Flake e E.D. Zanjani, "IN-UTERO HEMATOPOIETIC STEM-CELL TRANSPLANTATION - A STATUS-REPORT", JAMA, the journal of the American Medical Association, 278(11), 1997, pp. 932-937

Abstract

In utero hematopoietic stem cell transplantation is currently in its early stage of development, but it holds considerable promise as a therapeutic approach for the treatment of a large number of congenital hematologic diseases. Experimental evidence supports the concept of the early gestational fetus as a favorable recipient for cellular therapy. Unique aspects of normal hematologic and immunologic ontogeny allow engraftment and long-term persistence of transplanted hematopoietic stem cells without the requirement for myeloablation or immunosuppression. To date, 21 in utero transplants have been reported. Success has been limited to 4 fetuses, all with immunodeficiency disorders. Despite this limited evidence of clinical efficacy, interest in stem cell transplantation has been gaining momentum, and clinical application is likely to increase. Parallel advances in prenatal diagnosis, fetal intervention, and hematopoietic stem cell technology have removed many of thepractical, technical, and ethical obstacles to clinical application. This progress has been accompanied by an increase in the number of centers with both the stated interest and perceived expertise to develop clinical programs. However, there is currently limited consensus amonginvestigators on many important issues, such as the mode or timing ofin utero transplantation, the ideal source or dose of donor cells, estimation of maternal and fetal risks, appropriate candidate diseases for treatment, and important ethical considerations in counseling and therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 22:17:01